Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Long-term Vaccine Therapy with Autologous Whole Tumor Cell-pulsed Dendritic Cells for a Patient with Recurrent Rectal Carcinoma. H. ONISHI, T. MORISAKI, E. BABA, M. NAKAMURA, S. INABA, H. KUROKI, K. MATSUMOTO, M. KATANO (Fukuoka; Kumamoto; Kanagawa, Japan) .................................................. 3995


Assessment of ‘Cancer-prone Personality’ Characteristics in Healthy Study Subjects and in Patients with Breast Disease and Breast Cancer Using the Commitment Questionnaire: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) ........................................................................................................... 4013

Measurement of Pessimism: Hopelessness Scale in Healthy Study Subjects, and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) ........................................................................................................................................................................ 4019


3D Breast Ultrasound: A Significant Predictor in Breast Cancer Reduction under Pre-operative Chemotherapy. M. WARM, V. DUDA, C. EICHLER, N. HARBECK, A. GOSSMANN, A. THOMAS, M. HOOPMANN, R. OHLINGER, M. BREIDENBACH, R.E. KATES (Cologne; Marburg; Berlin; Greifswald; Otterfing, Germany) ......................................................................................................................... 4039

Nomogram for Suboptimal Cytoreduction at Primary Surgery for Advanced Stage Ovarian Cancer. C.G. GERESTEIN, M.J. EIJKEMANS, J. BAKKER, O.E. ELGERSMA, M.E.L VAN DER BURG, G.S. KOOI, C.W. BURGER (Rotterdam; Utrecht; Dordrecht, Netherlands) ......................................................................................................................... 4043

Errata ........................................................................................................................................................................ 4051

* Review (page 3645)

ADH-1 in the Treatment of Metastatic Adrenocortical Carcinoma - Case Report. N. YAROM, D. STEWART, L. AVRUCH, R. MALIK, J. WELLS, D.J. JONKER (Ottawa, ON, Canada; Houston, TX, USA) .............. 3921

Hepatic Intra-arterial Cetuximab in Combination with 5-Fluorouracil and Cisplatin as Salvage Treatment for Sorafenib-refractory Hepatocellular Carcinoma. G. POGGI, B. MONTAGNA, F. MELCHIORRE, P. QUARETTI, A. DELMONTE, A. RICCARDI, B. TAGLIAFERRI, F. SOTTOTETTI, P. DI CESARE, M.G. STELLA, L. VILLANI, M. ZORZETTO, G. GRECO, G. CORNALBA, G. BERNARDO (Pavia; Milan, Italy) .................. 3927

Repeated Localized Treatment for Extranodal Marginal Zone Lymphoma – Case Report and Review of Literature. C.E. SCHÖNKNECHT, C. NIEDER, M. MOLLS, S.T. ASTNER (Munich, Germany; Bodø; Tromsø, Norway) .................................................................................................................. 3933

Association of hOGG1 and XPD Polymorphisms with Urothelial Carcinoma in Taiwan. Y.-H. WANG, S.-D. YEH, K.-H. SHEN, C.-H. SHEN, M.-C. TUNG, C.-T. LIU, H.-Y. CHIOU (Taipei; Tainan; Chiayi; Taichung, Taiwan, ROC) ............................................................................................................. 3935

Polymorphisms in DNA Repair Gene XRCC1 and Skin Cancer Risk: A Meta-analysis. H. ZHANG, W. LI, M.J. FRANKLIN, A.Z. DUDEK (New York, NY; Lexington, KY; Minneapolis, MN, USA) ............... 3939


Prevalence of Level V Metastases in Node-positive Head and Neck Squamous Cell Carcinoma. S. WIEGAND, A.P. ZIMMERMANN, A.M. SESTERHENN, J.A. WERNER (Marburg, Germany) .......................................................... 3953


Arterial Blood Pressure, Serum Calcium and PTH in Elderly Men with Parathyroid Tumors and Primary Hyperparathyroidism. F. LUMACHI, V. CAMOZZI, G. LUISETTO, S. ZANELLA, S.M.M. BASSO (Padova; Pordenone, Italy) .................................................................................................................. 3969

Beckwith-Wiedemann Syndrome: Potassium Ascorbate with Ribose Therapy in a Syndrome with High Neoplastic Risk. C. ANICHINI, C. LO RIZZO, M. LONGINI, G. PAOLI, R.M. DI BARTOLO, F. PROIETTI, G. BUONOCORE (Siena; Firenze, Italy) ...................................................................................................................... 3973

Characterization of Dysplastic Nodules, Early Hepatocellular Carcinoma and Progressed Hepatocellular Carcinoma in Cirrhosis with Contrast-Enhanced Ultrasound. A. GIORGIO, G. CALISTI, A. DI SARNO, N. FARCELLA, G. DE STEFANO, U. SCOGNAMIGLIO, V. GIORGIO (Naples; Rome, Italy) ................................. 3977


Resection of Solitary Metachronous Lymph Node Metastasis from Hepatocellular Carcinoma Following Transarterial Chemotherapy with Cisplatin: A Case Report. T. KUROKAWA, S. YAMAZAKI, M. MORIGUCHI, M. AOKI, Y. WATANABE, T. HIGAKI, T. TAKAYAMA (Tokyo, Japan) ............................................................ 3991

Contents continued on the preceding page
Phosphorylation of STAT3 in Head and Neck Cancer Requires p38 MAPKinase, whereas Phosphorylation of STAT1 Occurs via a Different Signaling Pathway. C. RIEBE, R. PRIES, K.N. SCHROEDER, B. WOLLENBERG (Lübeck, Germany) .......................................................... 3819


Detection of TFPI2 Methylation in the Serum of Gastric Cancer Patients. K. HIBI, T. GOTO, A. SHIRAHATA, M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA (Yokohama, Japan) .......................................................... 3835

Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer. T. HIRANO, K. HIROSE, K. SAKURAI, M. MAKISHIMA, K. SASAKI, S. AMANO (Tokyo, Japan) .......................................................... 3839

Relationship between TYMS and ERCC1 mRNA Expression and In Vitro Chemosensitivity in Colorectal Cancer. Y.B. CHO, H.J. CHUNG, W.Y. LEE, S.H. CHOI, H.C. KIM, S.H. YUN, H.-K. CHUN (Seoul, South Korea) .......................................................... 3843

Mode of Cell Death Associated with Adenovirus-mediated Suicide Gene Therapy in HNSCC Tumor Model. D. SRIVASTAVA, G. JOSHI, K. SOMASUNDARAM, R. MULLERKAR (Mumbai; Bangalore, India) .......................................................... 3851

Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGF Expression. T. ZHANG, M. LIU, C. WANG, C. LIN, Y. SUN, D. JIN (Harbin, PR China) .......................................................... 3859

Clinical Studies


Prolonged Administration of Temozolomide in Adult Patients with Anaplastic Glioma. C.F. FREYSCHLAG, D.R. SMOLCZYK, E. JANZEN, K. SCHMIEDER, C. THOMÉ, F. LOHR, F. WENZ, C. WEISS, J. TUETTENBERG, M. SEIZ (Innsbruck, Austria; Mannheim; Idar-Oberstein, Germany) .......................................................... 3873

Serum N-Telopeptide of Type I Collagen and Bone Alkaline Phosphatase and their Relationship in Patients with Non-small Cell Lung Carcinoma and Bone Metastases. Preliminary Results. F. LUMACHI, F. MARINO, G. FANTI, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy) .......................................................... 3879

Correlation of Gene Expression of ATP-binding Cassette Protein and Tyrosine Kinase Signaling Pathway in Patients with Hepatocellular Carcinoma. K. HOFFMANN, L. SHIBO, Z. XIAO, T. LONGERICH, M.W. BÜCHLER, P. SCHEMMER (Heidelberg, Germany) .......................................................... 3883


Ethnic Differences in Neuroendocrine Expression in Prostate Cancer Tissue. T.B. DORFF, S.V. LIU, S. XIONG, J. CAI, D. HAWES, J. PINSKI (Los Angeles, CA, USA) .......................................................... 3897

Patients’ Satisfaction with Different Modalities of Prostate Cancer Therapy – A Retrospective Survey among 634 Patients. W. WAGNER, T. BÖLLING, C. HAMBRUEGGE, J. HARTLAPP, M.G. KRUKEMEYER (Osnabrück; Externthal, Germany) .......................................................... 3903


Contents continued on the preceding page
Melanocyte-specific Immune Response in a Patient with Multiple Regressing Nevi and a History of Melanoma. R. SPEECKAERT, N. VAN GEEL, R.M. LUITEN, M. VAN GELE, M. SPEECKAERT, J. LAMBERT, K. VERMAELEN, E.P.M. TJIN, L. BROCHEZ (Ghent, Belgium; Amsterdam, Netherlands) ................................................................. 3697

MSC-TRAIL-mediated HepG2 Cell Death in Direct and Indirect Co-cultures. X.-Y. SUN, J. NONG, K. QIN, H. LU, M.R. MONIRI, L.-J. DAI, G.L. WARNOCK (Nanning, PR China; Vancouver, BC, Canada) ................. 3705

Cell to Cell Interactions Influence Sensitivity of Liver Cell Lines during Hyperthermia. U. MAYRAUSER, P. STIEGLER, V. STADLBAUER, S. KOESTENBAUER, B. LEBER, K. KONRAD, F. IBERER, K. TSCHELIESNIGG (Graz, Austria) ........................................................................................................... 3713

Novel Curcumin Analogs, GO-Y030 and GO-Y078, Are Multitargeted Agents with Enhanced Abilities for Multiple Myeloma. C. KUDO, H. YAMAKOSHI, A. SATO, H. OHORI, C. ISHIOKA, Y. IWABUCHI, H. SHIBATA (Akita; Sendai, Japan) ........................................................................................................................................... 3719

Cell Death Forms and HSP70 Expression in U87 Cells after Ionizing Radiation and/or Chemotherapy. A. PAOLINI, F. PASI, A. FACOETTI, G. MAZZINI, F. CORBELLA, R. DI LIBERTO, R. NANO (Pavia, Italy) .......................................................... 3727

Indole-3-carbinol Inhibits Telomerase Activity and Gene Expression in Prostate Cancer Cell Lines. S. ADLER, G. RASHID, A. KLEIN (Kfar Saba; Tel Aviv, Israel) ................................................................................................................................. 3733


Mechanisms Underlying Gemcitabine Resistance in Pancreatic Cancer and Sensitisation by the iMiD™ Lenalidomide. R.A. FRYER, B. BARLETT, C. GALUSTIAN, A.G. DALGLEISH (London, UK; Summit, NJ, USA) ........................................................................................................................................... 3747

5-Azacytidine Reverses Drug Resistance in Bladder Cancer Cells. K. RAMACHANDRAN, E. GORDIAN, R. SINGAL (Miami, FL, USA) ................................................................................................................................................. 3757


Relationship between LAT1 Expression and Response to Platinum-based Chemotherapy in Non-small Cell Lung Cancer Patients with Postoperative Recurrence. K. KAIRA, T. TAKAHASHI, H. MURAKAMI, T. SHUKUYA, H. KENMOTSU, T. NAITO, N. ORIUCHI, Y. KANAI, M. ENDO, H. KONDO, T. NAKAJIMA, N. YAMAMOTO (Shizuoka; Gunma; Osaka, Japan) .......................................................................................................................... 3775


Synergism from Combinations of Cisplatin and Oxaliplatin with Quercetin and Thymoquinone in Human Ovarian Tumour Models. M.U. NESSA, P. BEALE, C. CHAN, J.Q. YU, F. HUQ (lidcombe; Concord, NSW, Australia) ........................................................................................................................................... 3789

Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent. S. SREEVALSAN, S. JOSEPH, I. JUTOORU, G. CHADALAPAKA, S.H. SAFE (College Station; Houston, TX, USA) ............................................................................................................................................. 3799

An Active Endocytosis Pathway Is Required for the Cytotoxic Effects of Glycosylated Antitumor Ether Lipids. P. SAMADDER, H.-S. BYUN, R. BITTMAN, G. ARTHUR (Winnipeg, MB, Canada; Flushing, NY, USA) ................................................................................................................................................. 3809

Contents continued on the preceding page